阿托伐他汀对早发冠心病急性心肌梗死患者的临床疗效

Clinical Efficacy of Atorvastatin for Treating Patients with Premat ure Coronary Artery Disease with Acute Myocardial Infarction

目的探究阿托伐他汀对早发冠心病急性心肌梗死患者的临床疗效。方法选取2016年4月~2019年2月收治的早发冠心病急性心肌梗死患者74例,均行冠脉介入治疗,随机分为两组(传统组与试验组),每组37例。在常规治疗的基础上,传统组给予瑞舒伐他汀治疗,试验组给予阿托伐他汀治疗。对比两组血脂及心功能指标和不良心血管事件发生率。结果不良心血管事件:试验组总发生率5.40%,传统组发生率24.33%,两组差异具有统计学意义(P<0.05);试验组治疗后血脂指标与心功能指标均优于传统组,两组差异具有统计学差异(P<0.05)。结论阿托伐他汀能有效改善早发冠心病急性心肌梗死患者心功能及血脂水平,疗效安全可靠。

Objective:To investigate the clinical efficacy of atorvastatin for treating patients with premature coronary artery disease(PCAD)with acute myocardial infarction(AMI).Methods:Totally,74 patients with premature coronary artery disease(PCAD)with acute myocardial infarction(AMI)were admitted and treated in our hospital from April 2016 to February 2019.They were randomly divided into test group and control group with 37 patients in each group.Patients in control group were treated with rosuvastatin,while patients in test group were treated with atorvastatin.The blood lipid,cardiac function,and adverse cardiovascular events were compared between the two groups.Results:The incidence of adverse cardiovascular events in test group(5.40%)was significantly lower than that in control group(24.33%).The indexes of blood lipid and cardiac function in test group were significant better than those in control group(P<0.05).Conclusions:Atorvastatin is efficacious and reliable for treating patients with premature coronary artery disease with acute myocardial infarction,which can improve cardiac function and blood lipid.